Thrive Earlier Detection Stock

thrivedetect.comHealthcareFounded: 2019Funding to Date: $110MM

Thrive is the developer a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages.

Register for Details

For more details on financing and valuation for Thrive Earlier Detection, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Thrive Earlier Detection.

Register Today

Team

Management Team

Kenneth Kinzler Ph.D
Co-Founder & Board Member
Christoph Lengauer Ph.D
Co-Founder, Board Member & Chief Innovation Officer
Isaac Ro
Chief Financial Officer
Bert Vogelstein MD
Co-Founder
Samantha Singer
Chief Operating Officer
Steven Kafka Ph.D
Executive Chairman

Board Members

Christoph Lengauer Ph.D
Steven Kafka Ph.D
Kenneth Kinzler Ph.D
Alexis Borisy
Third Rock Ventures
Michael Pellini MD
Section 32

Other companies like Thrive Earlier Detection in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Thrive Earlier Detection Corp., a Cambridge, MA-based company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care, raised $257m in Series B financing
Thrive Earlier Detection Corp., a company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care,
Thrive Earlier Detection Corp., a company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care,